NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421

/PRNewswire/ -- United BioPharma (UBP) announced today that the U.S. Food and Drug Administration (FDA) has approved a phase 2 clinical trial IND submitted by...

Related Keywords

Taipei ,T Ai Pei ,Taiwan ,Shugene Lynn ,Drug Administration ,Us National Institute Of Allergy ,Infectious Diseases ,Open Label Phase ,Optimized Background Antiretroviral Therapy ,Multi Drug Resistant ,United Biopharma Inc ,